Gilead sours on the ‘don’t eat me’ business
Gilead will no longer develop magrolimab, a treatment targeting the “don’t eat me signal” exploited by tumors in blood cancer after another clinical setback that makes its $5 billion investment in…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.
What's Your Reaction?
